JAK-IN-17

• UNSPSC Description:

  JAK-IN-17 is a potent inhibitor of JAK. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1)[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jak-in-17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC([C@@H]([C@H](C(O)=O)O)O)=O.CCC1=CC(O)=C(C=C1C2=CC(F)=C3C(NN=C3C4=NC5=C(N4)CCN(C5)C(CN6CCO[C@H](C6)C)=O)=C2)F

• Molecular Weight:

  684.69

• References & Citations:

  [1]Zhang Chen, et al. An indazole derivative and its application in medicine. Patent WO2021185305A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported